A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$58.80
arrow_downward
-1.74%(-1.04) 1D
Okt 19, 11:16:17 AM GMT-3 · BRL
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa A1LN34...
Buksan
R$58.86
Mataas
R$58.86
Mababa
R$58.80
Mkt. cap
31.23B
Avg. na dami
447.00
Dami
237.00
Mataas nang 52-wk
R$130.75
Mababa nang 52-wk
R$50.25
Mga natitirang share
133.81M
Bilang ng mga empleyado
2K
Buksan
R$58.86
Mataas
R$58.86
Mababa
R$58.80
Mkt. cap
31.23B
Avg. na dami
447.00
Dami
237.00
Mataas nang 52-wk
R$130.75
Mababa nang 52-wk
R$50.25
Mga natitirang share
133.81M
Bilang ng mga empleyado
2K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
The Business Journals
·
3 araw ang nakalipas
Alnylam founder's new biotech lands $200M in upsized IPO
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Tungkol sa Alnylam Pharmaceuticals Inc Bdr